nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR6—Alzheimer's disease	0.251	0.514	CbGaD
Duloxetine—HTR2A—Donepezil—Alzheimer's disease	0.124	0.509	CbGbCtD
Duloxetine—SLC6A4—Alzheimer's disease	0.0961	0.197	CbGaD
Duloxetine—HTR2A—Alzheimer's disease	0.0738	0.151	CbGaD
Duloxetine—CYP2D6—Alzheimer's disease	0.0675	0.138	CbGaD
Duloxetine—CYP2D6—Rivastigmine—Alzheimer's disease	0.0515	0.212	CbGbCtD
Duloxetine—CYP2D6—Donepezil—Alzheimer's disease	0.0412	0.169	CbGbCtD
Duloxetine—CYP2D6—Galantamine—Alzheimer's disease	0.0265	0.109	CbGbCtD
Duloxetine—HTR2C—choroid plexus—Alzheimer's disease	0.00981	0.171	CbGeAlD
Duloxetine—SLC6A2—locus ceruleus—Alzheimer's disease	0.00506	0.0882	CbGeAlD
Duloxetine—HTR2A—choroid plexus—Alzheimer's disease	0.00492	0.0858	CbGeAlD
Duloxetine—HTR2A—locus ceruleus—Alzheimer's disease	0.00304	0.053	CbGeAlD
Duloxetine—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.00297	0.0518	CbGeAlD
Duloxetine—HTR2C—telencephalic ventricle—Alzheimer's disease	0.00288	0.0501	CbGeAlD
Duloxetine—HTR2A—cerebellar cortex—Alzheimer's disease	0.00248	0.0432	CbGeAlD
Duloxetine—NPY1R—forebrain—Alzheimer's disease	0.00185	0.0322	CbGeAlD
Duloxetine—NPY1R—telencephalon—Alzheimer's disease	0.0017	0.0296	CbGeAlD
Duloxetine—HTR2A—telencephalic ventricle—Alzheimer's disease	0.00144	0.0251	CbGeAlD
Duloxetine—HTR6—forebrain—Alzheimer's disease	0.0013	0.0226	CbGeAlD
Duloxetine—HTR6—telencephalon—Alzheimer's disease	0.00119	0.0208	CbGeAlD
Duloxetine—NPY1R—nervous system—Alzheimer's disease	0.001	0.0175	CbGeAlD
Duloxetine—NPY1R—central nervous system—Alzheimer's disease	0.000965	0.0168	CbGeAlD
Duloxetine—SLC6A3—forebrain—Alzheimer's disease	0.000777	0.0135	CbGeAlD
Duloxetine—NPY1R—brain—Alzheimer's disease	0.000766	0.0133	CbGeAlD
Duloxetine—HTR2C—forebrain—Alzheimer's disease	0.000751	0.0131	CbGeAlD
Duloxetine—SLC6A3—telencephalon—Alzheimer's disease	0.000714	0.0124	CbGeAlD
Duloxetine—HTR2A—blood vessel—Alzheimer's disease	0.000714	0.0124	CbGeAlD
Duloxetine—SLC6A4—forebrain—Alzheimer's disease	0.000712	0.0124	CbGeAlD
Duloxetine—HTR6—nervous system—Alzheimer's disease	0.000705	0.0123	CbGeAlD
Duloxetine—HTR2C—telencephalon—Alzheimer's disease	0.00069	0.012	CbGeAlD
Duloxetine—HTR6—central nervous system—Alzheimer's disease	0.000679	0.0118	CbGeAlD
Duloxetine—SLC6A4—telencephalon—Alzheimer's disease	0.000655	0.0114	CbGeAlD
Duloxetine—SLC6A2—forebrain—Alzheimer's disease	0.000627	0.0109	CbGeAlD
Duloxetine—SLC6A2—telencephalon—Alzheimer's disease	0.000576	0.01	CbGeAlD
Duloxetine—HTR6—brain—Alzheimer's disease	0.000539	0.00939	CbGeAlD
Duloxetine—HTR2A—embryo—Alzheimer's disease	0.000426	0.00742	CbGeAlD
Duloxetine—SLC6A3—nervous system—Alzheimer's disease	0.000422	0.00735	CbGeAlD
Duloxetine—HTR2C—nervous system—Alzheimer's disease	0.000408	0.0071	CbGeAlD
Duloxetine—SLC6A3—central nervous system—Alzheimer's disease	0.000406	0.00707	CbGeAlD
Duloxetine—SLC6A3—cerebellum—Alzheimer's disease	0.000397	0.00691	CbGeAlD
Duloxetine—HTR2C—central nervous system—Alzheimer's disease	0.000392	0.00684	CbGeAlD
Duloxetine—Atomoxetine—HTR6—Alzheimer's disease	0.000392	0.172	CrCbGaD
Duloxetine—SLC6A4—nervous system—Alzheimer's disease	0.000386	0.00673	CbGeAlD
Duloxetine—HTR2A—forebrain—Alzheimer's disease	0.000377	0.00656	CbGeAlD
Duloxetine—SLC6A4—central nervous system—Alzheimer's disease	0.000372	0.00648	CbGeAlD
Duloxetine—HTR2A—telencephalon—Alzheimer's disease	0.000346	0.00603	CbGeAlD
Duloxetine—CYP2D6—forebrain—Alzheimer's disease	0.000343	0.00598	CbGeAlD
Duloxetine—Protriptyline—SLC6A4—Alzheimer's disease	0.000342	0.15	CrCbGaD
Duloxetine—SLC6A2—nervous system—Alzheimer's disease	0.00034	0.00593	CbGeAlD
Duloxetine—SLC6A2—central nervous system—Alzheimer's disease	0.000328	0.00571	CbGeAlD
Duloxetine—SLC6A3—brain—Alzheimer's disease	0.000322	0.00561	CbGeAlD
Duloxetine—CYP2D6—telencephalon—Alzheimer's disease	0.000316	0.0055	CbGeAlD
Duloxetine—HTR2C—brain—Alzheimer's disease	0.000312	0.00543	CbGeAlD
Duloxetine—SLC6A4—brain—Alzheimer's disease	0.000295	0.00515	CbGeAlD
Duloxetine—SLC6A2—brain—Alzheimer's disease	0.00026	0.00453	CbGeAlD
Duloxetine—Cinacalcet—CYP2D6—Alzheimer's disease	0.000257	0.113	CrCbGaD
Duloxetine—Protriptyline—CYP2D6—Alzheimer's disease	0.00024	0.105	CrCbGaD
Duloxetine—Fluoxetine—SLC6A4—Alzheimer's disease	0.000233	0.102	CrCbGaD
Duloxetine—HTR2A—nervous system—Alzheimer's disease	0.000204	0.00356	CbGeAlD
Duloxetine—HTR2A—central nervous system—Alzheimer's disease	0.000197	0.00343	CbGeAlD
Duloxetine—HTR2A—cerebellum—Alzheimer's disease	0.000192	0.00335	CbGeAlD
Duloxetine—CYP2D6—nervous system—Alzheimer's disease	0.000186	0.00324	CbGeAlD
Duloxetine—CYP2D6—central nervous system—Alzheimer's disease	0.000179	0.00312	CbGeAlD
Duloxetine—Fluoxetine—HTR2A—Alzheimer's disease	0.000179	0.0787	CrCbGaD
Duloxetine—CYP2D6—cerebellum—Alzheimer's disease	0.000175	0.00305	CbGeAlD
Duloxetine—Fluoxetine—CYP2D6—Alzheimer's disease	0.000164	0.072	CrCbGaD
Duloxetine—HTR2A—brain—Alzheimer's disease	0.000156	0.00272	CbGeAlD
Duloxetine—Tachycardia—Galantamine—Alzheimer's disease	0.000153	0.000965	CcSEcCtD
Duloxetine—Oedema peripheral—Memantine—Alzheimer's disease	0.000153	0.000965	CcSEcCtD
Duloxetine—Arrhythmia—Donepezil—Alzheimer's disease	0.000153	0.000963	CcSEcCtD
Duloxetine—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000153	0.000963	CcSEcCtD
Duloxetine—Connective tissue disorder—Memantine—Alzheimer's disease	0.000153	0.000962	CcSEcCtD
Duloxetine—Skin disorder—Galantamine—Alzheimer's disease	0.000153	0.00096	CcSEcCtD
Duloxetine—Urethral disorder—Memantine—Alzheimer's disease	0.000152	0.00096	CcSEcCtD
Duloxetine—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000152	0.000958	CcSEcCtD
Duloxetine—Hepatitis—Rivastigmine—Alzheimer's disease	0.000152	0.000958	CcSEcCtD
Duloxetine—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000152	0.000956	CcSEcCtD
Duloxetine—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000151	0.000953	CcSEcCtD
Duloxetine—Hallucination—Rivastigmine—Alzheimer's disease	0.000151	0.000953	CcSEcCtD
Duloxetine—Alopecia—Donepezil—Alzheimer's disease	0.000151	0.000953	CcSEcCtD
Duloxetine—Pharyngitis—Rivastigmine—Alzheimer's disease	0.000151	0.000951	CcSEcCtD
Duloxetine—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.00015	0.000946	CcSEcCtD
Duloxetine—Mental disorder—Donepezil—Alzheimer's disease	0.00015	0.000945	CcSEcCtD
Duloxetine—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.00015	0.000944	CcSEcCtD
Duloxetine—Visual impairment—Memantine—Alzheimer's disease	0.00015	0.000944	CcSEcCtD
Duloxetine—Atomoxetine—SLC6A4—Alzheimer's disease	0.00015	0.0658	CrCbGaD
Duloxetine—Anorexia—Galantamine—Alzheimer's disease	0.00015	0.000942	CcSEcCtD
Duloxetine—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.00015	0.000941	CcSEcCtD
Duloxetine—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000149	0.000939	CcSEcCtD
Duloxetine—Malnutrition—Donepezil—Alzheimer's disease	0.000149	0.000939	CcSEcCtD
Duloxetine—Erythema—Donepezil—Alzheimer's disease	0.000149	0.000939	CcSEcCtD
Duloxetine—Erythema multiforme—Memantine—Alzheimer's disease	0.000147	0.000926	CcSEcCtD
Duloxetine—Flatulence—Donepezil—Alzheimer's disease	0.000147	0.000925	CcSEcCtD
Duloxetine—Visual impairment—Rivastigmine—Alzheimer's disease	0.000147	0.000923	CcSEcCtD
Duloxetine—Tension—Donepezil—Alzheimer's disease	0.000146	0.000921	CcSEcCtD
Duloxetine—Dysgeusia—Donepezil—Alzheimer's disease	0.000146	0.000919	CcSEcCtD
Duloxetine—Eye disorder—Memantine—Alzheimer's disease	0.000145	0.000915	CcSEcCtD
Duloxetine—Tinnitus—Memantine—Alzheimer's disease	0.000145	0.000913	CcSEcCtD
Duloxetine—Nervousness—Donepezil—Alzheimer's disease	0.000145	0.000912	CcSEcCtD
Duloxetine—Cardiac disorder—Memantine—Alzheimer's disease	0.000144	0.000909	CcSEcCtD
Duloxetine—Flushing—Memantine—Alzheimer's disease	0.000144	0.000909	CcSEcCtD
Duloxetine—Back pain—Donepezil—Alzheimer's disease	0.000144	0.000908	CcSEcCtD
Duloxetine—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000144	0.000906	CcSEcCtD
Duloxetine—Muscle spasms—Donepezil—Alzheimer's disease	0.000143	0.000903	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000143	0.000901	CcSEcCtD
Duloxetine—CYP2D6—brain—Alzheimer's disease	0.000142	0.00248	CbGeAlD
Duloxetine—Eye disorder—Rivastigmine—Alzheimer's disease	0.000142	0.000895	CcSEcCtD
Duloxetine—Insomnia—Galantamine—Alzheimer's disease	0.000142	0.000894	CcSEcCtD
Duloxetine—Tinnitus—Rivastigmine—Alzheimer's disease	0.000142	0.000893	CcSEcCtD
Duloxetine—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000141	0.000889	CcSEcCtD
Duloxetine—Flushing—Rivastigmine—Alzheimer's disease	0.000141	0.000889	CcSEcCtD
Duloxetine—Angiopathy—Memantine—Alzheimer's disease	0.000141	0.000888	CcSEcCtD
Duloxetine—Paraesthesia—Galantamine—Alzheimer's disease	0.000141	0.000888	CcSEcCtD
Duloxetine—Vision blurred—Donepezil—Alzheimer's disease	0.000141	0.000885	CcSEcCtD
Duloxetine—Immune system disorder—Memantine—Alzheimer's disease	0.00014	0.000884	CcSEcCtD
Duloxetine—Mediastinal disorder—Memantine—Alzheimer's disease	0.00014	0.000882	CcSEcCtD
Duloxetine—Tremor—Donepezil—Alzheimer's disease	0.00014	0.00088	CcSEcCtD
Duloxetine—Somnolence—Galantamine—Alzheimer's disease	0.00014	0.000879	CcSEcCtD
Duloxetine—Chills—Memantine—Alzheimer's disease	0.00014	0.000879	CcSEcCtD
Duloxetine—Arrhythmia—Memantine—Alzheimer's disease	0.000139	0.000875	CcSEcCtD
Duloxetine—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000138	0.000871	CcSEcCtD
Duloxetine—Dyspepsia—Galantamine—Alzheimer's disease	0.000138	0.00087	CcSEcCtD
Duloxetine—Angiopathy—Rivastigmine—Alzheimer's disease	0.000138	0.000869	CcSEcCtD
Duloxetine—Anaemia—Donepezil—Alzheimer's disease	0.000138	0.000868	CcSEcCtD
Duloxetine—Alopecia—Memantine—Alzheimer's disease	0.000137	0.000865	CcSEcCtD
Duloxetine—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000137	0.000863	CcSEcCtD
Duloxetine—Agitation—Donepezil—Alzheimer's disease	0.000137	0.000863	CcSEcCtD
Duloxetine—Chills—Rivastigmine—Alzheimer's disease	0.000137	0.00086	CcSEcCtD
Duloxetine—Decreased appetite—Galantamine—Alzheimer's disease	0.000137	0.000859	CcSEcCtD
Duloxetine—Mental disorder—Memantine—Alzheimer's disease	0.000136	0.000858	CcSEcCtD
Duloxetine—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000136	0.000856	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000136	0.000854	CcSEcCtD
Duloxetine—Malnutrition—Memantine—Alzheimer's disease	0.000135	0.000852	CcSEcCtD
Duloxetine—Fatigue—Galantamine—Alzheimer's disease	0.000135	0.000852	CcSEcCtD
Duloxetine—Malaise—Donepezil—Alzheimer's disease	0.000134	0.000847	CcSEcCtD
Duloxetine—Alopecia—Rivastigmine—Alzheimer's disease	0.000134	0.000846	CcSEcCtD
Duloxetine—Constipation—Galantamine—Alzheimer's disease	0.000134	0.000845	CcSEcCtD
Duloxetine—Vertigo—Donepezil—Alzheimer's disease	0.000134	0.000843	CcSEcCtD
Duloxetine—Syncope—Donepezil—Alzheimer's disease	0.000134	0.000842	CcSEcCtD
Duloxetine—Flatulence—Memantine—Alzheimer's disease	0.000133	0.00084	CcSEcCtD
Duloxetine—Mental disorder—Rivastigmine—Alzheimer's disease	0.000133	0.000839	CcSEcCtD
Duloxetine—Tension—Memantine—Alzheimer's disease	0.000133	0.000836	CcSEcCtD
Duloxetine—Dysgeusia—Memantine—Alzheimer's disease	0.000133	0.000835	CcSEcCtD
Duloxetine—Erythema—Rivastigmine—Alzheimer's disease	0.000132	0.000834	CcSEcCtD
Duloxetine—Malnutrition—Rivastigmine—Alzheimer's disease	0.000132	0.000834	CcSEcCtD
Duloxetine—Nervousness—Memantine—Alzheimer's disease	0.000132	0.000828	CcSEcCtD
Duloxetine—Loss of consciousness—Donepezil—Alzheimer's disease	0.000131	0.000825	CcSEcCtD
Duloxetine—Back pain—Memantine—Alzheimer's disease	0.000131	0.000825	CcSEcCtD
Duloxetine—Flatulence—Rivastigmine—Alzheimer's disease	0.000131	0.000822	CcSEcCtD
Duloxetine—Cough—Donepezil—Alzheimer's disease	0.00013	0.000819	CcSEcCtD
Duloxetine—Tension—Rivastigmine—Alzheimer's disease	0.00013	0.000818	CcSEcCtD
Duloxetine—Dysgeusia—Rivastigmine—Alzheimer's disease	0.00013	0.000817	CcSEcCtD
Duloxetine—Feeling abnormal—Galantamine—Alzheimer's disease	0.000129	0.000815	CcSEcCtD
Duloxetine—Convulsion—Donepezil—Alzheimer's disease	0.000129	0.000813	CcSEcCtD
Duloxetine—Hypertension—Donepezil—Alzheimer's disease	0.000129	0.000811	CcSEcCtD
Duloxetine—Nervousness—Rivastigmine—Alzheimer's disease	0.000129	0.00081	CcSEcCtD
Duloxetine—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000128	0.000808	CcSEcCtD
Duloxetine—Back pain—Rivastigmine—Alzheimer's disease	0.000128	0.000807	CcSEcCtD
Duloxetine—Vision blurred—Memantine—Alzheimer's disease	0.000128	0.000803	CcSEcCtD
Duloxetine—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000127	0.000802	CcSEcCtD
Duloxetine—Myalgia—Donepezil—Alzheimer's disease	0.000127	0.000799	CcSEcCtD
Duloxetine—Arthralgia—Donepezil—Alzheimer's disease	0.000127	0.000799	CcSEcCtD
Duloxetine—Chest pain—Donepezil—Alzheimer's disease	0.000127	0.000799	CcSEcCtD
Duloxetine—Tremor—Memantine—Alzheimer's disease	0.000127	0.000799	CcSEcCtD
Duloxetine—Anxiety—Donepezil—Alzheimer's disease	0.000127	0.000796	CcSEcCtD
Duloxetine—Ill-defined disorder—Memantine—Alzheimer's disease	0.000126	0.000791	CcSEcCtD
Duloxetine—Discomfort—Donepezil—Alzheimer's disease	0.000125	0.00079	CcSEcCtD
Duloxetine—Anaemia—Memantine—Alzheimer's disease	0.000125	0.000788	CcSEcCtD
Duloxetine—Vision blurred—Rivastigmine—Alzheimer's disease	0.000125	0.000786	CcSEcCtD
Duloxetine—Agitation—Memantine—Alzheimer's disease	0.000124	0.000783	CcSEcCtD
Duloxetine—Dry mouth—Donepezil—Alzheimer's disease	0.000124	0.000782	CcSEcCtD
Duloxetine—Abdominal pain—Galantamine—Alzheimer's disease	0.000124	0.000782	CcSEcCtD
Duloxetine—Body temperature increased—Galantamine—Alzheimer's disease	0.000124	0.000782	CcSEcCtD
Duloxetine—Tremor—Rivastigmine—Alzheimer's disease	0.000124	0.000781	CcSEcCtD
Duloxetine—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000123	0.000774	CcSEcCtD
Duloxetine—Confusional state—Donepezil—Alzheimer's disease	0.000123	0.000773	CcSEcCtD
Duloxetine—Anaemia—Rivastigmine—Alzheimer's disease	0.000122	0.000771	CcSEcCtD
Duloxetine—Malaise—Memantine—Alzheimer's disease	0.000122	0.000769	CcSEcCtD
Duloxetine—Agitation—Rivastigmine—Alzheimer's disease	0.000122	0.000766	CcSEcCtD
Duloxetine—Oedema—Donepezil—Alzheimer's disease	0.000122	0.000766	CcSEcCtD
Duloxetine—Vertigo—Memantine—Alzheimer's disease	0.000122	0.000766	CcSEcCtD
Duloxetine—Syncope—Memantine—Alzheimer's disease	0.000121	0.000764	CcSEcCtD
Duloxetine—Leukopenia—Memantine—Alzheimer's disease	0.000121	0.000763	CcSEcCtD
Duloxetine—Infection—Donepezil—Alzheimer's disease	0.000121	0.000761	CcSEcCtD
Duloxetine—Shock—Donepezil—Alzheimer's disease	0.00012	0.000754	CcSEcCtD
Duloxetine—Palpitations—Memantine—Alzheimer's disease	0.00012	0.000753	CcSEcCtD
Duloxetine—Malaise—Rivastigmine—Alzheimer's disease	0.000119	0.000752	CcSEcCtD
Duloxetine—Nervous system disorder—Donepezil—Alzheimer's disease	0.000119	0.000751	CcSEcCtD
Duloxetine—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000119	0.00075	CcSEcCtD
Duloxetine—Vertigo—Rivastigmine—Alzheimer's disease	0.000119	0.000749	CcSEcCtD
Duloxetine—Loss of consciousness—Memantine—Alzheimer's disease	0.000119	0.000749	CcSEcCtD
Duloxetine—Syncope—Rivastigmine—Alzheimer's disease	0.000119	0.000748	CcSEcCtD
Duloxetine—Cough—Memantine—Alzheimer's disease	0.000118	0.000744	CcSEcCtD
Duloxetine—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000118	0.000741	CcSEcCtD
Duloxetine—Convulsion—Memantine—Alzheimer's disease	0.000117	0.000739	CcSEcCtD
Duloxetine—Palpitations—Rivastigmine—Alzheimer's disease	0.000117	0.000737	CcSEcCtD
Duloxetine—Hypertension—Memantine—Alzheimer's disease	0.000117	0.000736	CcSEcCtD
Duloxetine—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000116	0.000733	CcSEcCtD
Duloxetine—Anorexia—Donepezil—Alzheimer's disease	0.000116	0.00073	CcSEcCtD
Duloxetine—Hypersensitivity—Galantamine—Alzheimer's disease	0.000116	0.000728	CcSEcCtD
Duloxetine—Cough—Rivastigmine—Alzheimer's disease	0.000116	0.000728	CcSEcCtD
Duloxetine—Chest pain—Memantine—Alzheimer's disease	0.000115	0.000726	CcSEcCtD
Duloxetine—Myalgia—Memantine—Alzheimer's disease	0.000115	0.000726	CcSEcCtD
Duloxetine—Arthralgia—Memantine—Alzheimer's disease	0.000115	0.000726	CcSEcCtD
Duloxetine—Atomoxetine—HTR2A—Alzheimer's disease	0.000115	0.0506	CrCbGaD
Duloxetine—Anxiety—Memantine—Alzheimer's disease	0.000115	0.000723	CcSEcCtD
Duloxetine—Convulsion—Rivastigmine—Alzheimer's disease	0.000115	0.000722	CcSEcCtD
Duloxetine—Hypertension—Rivastigmine—Alzheimer's disease	0.000114	0.00072	CcSEcCtD
Duloxetine—Discomfort—Memantine—Alzheimer's disease	0.000114	0.000717	CcSEcCtD
Duloxetine—Chest pain—Rivastigmine—Alzheimer's disease	0.000113	0.00071	CcSEcCtD
Duloxetine—Myalgia—Rivastigmine—Alzheimer's disease	0.000113	0.00071	CcSEcCtD
Duloxetine—Arthralgia—Rivastigmine—Alzheimer's disease	0.000113	0.00071	CcSEcCtD
Duloxetine—Dry mouth—Memantine—Alzheimer's disease	0.000113	0.00071	CcSEcCtD
Duloxetine—Asthenia—Galantamine—Alzheimer's disease	0.000113	0.000709	CcSEcCtD
Duloxetine—Anxiety—Rivastigmine—Alzheimer's disease	0.000112	0.000707	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000112	0.000705	CcSEcCtD
Duloxetine—Confusional state—Memantine—Alzheimer's disease	0.000111	0.000701	CcSEcCtD
Duloxetine—Discomfort—Rivastigmine—Alzheimer's disease	0.000111	0.000701	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000111	0.000698	CcSEcCtD
Duloxetine—Oedema—Memantine—Alzheimer's disease	0.000111	0.000696	CcSEcCtD
Duloxetine—Dry mouth—Rivastigmine—Alzheimer's disease	0.00011	0.000694	CcSEcCtD
Duloxetine—Insomnia—Donepezil—Alzheimer's disease	0.00011	0.000693	CcSEcCtD
Duloxetine—Infection—Memantine—Alzheimer's disease	0.00011	0.000691	CcSEcCtD
Duloxetine—Paraesthesia—Donepezil—Alzheimer's disease	0.000109	0.000688	CcSEcCtD
Duloxetine—Confusional state—Rivastigmine—Alzheimer's disease	0.000109	0.000686	CcSEcCtD
Duloxetine—Shock—Memantine—Alzheimer's disease	0.000109	0.000684	CcSEcCtD
Duloxetine—Nervous system disorder—Memantine—Alzheimer's disease	0.000108	0.000682	CcSEcCtD
Duloxetine—Somnolence—Donepezil—Alzheimer's disease	0.000108	0.000681	CcSEcCtD
Duloxetine—Thrombocytopenia—Memantine—Alzheimer's disease	0.000108	0.000681	CcSEcCtD
Duloxetine—Oedema—Rivastigmine—Alzheimer's disease	0.000108	0.000681	CcSEcCtD
Duloxetine—Tachycardia—Memantine—Alzheimer's disease	0.000108	0.000679	CcSEcCtD
Duloxetine—Diarrhoea—Galantamine—Alzheimer's disease	0.000107	0.000676	CcSEcCtD
Duloxetine—Infection—Rivastigmine—Alzheimer's disease	0.000107	0.000676	CcSEcCtD
Duloxetine—Skin disorder—Memantine—Alzheimer's disease	0.000107	0.000676	CcSEcCtD
Duloxetine—Dyspepsia—Donepezil—Alzheimer's disease	0.000107	0.000674	CcSEcCtD
Duloxetine—Hyperhidrosis—Memantine—Alzheimer's disease	0.000107	0.000673	CcSEcCtD
Duloxetine—Shock—Rivastigmine—Alzheimer's disease	0.000106	0.00067	CcSEcCtD
Duloxetine—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000106	0.000667	CcSEcCtD
Duloxetine—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000106	0.000666	CcSEcCtD
Duloxetine—Decreased appetite—Donepezil—Alzheimer's disease	0.000106	0.000666	CcSEcCtD
Duloxetine—Tachycardia—Rivastigmine—Alzheimer's disease	0.000106	0.000664	CcSEcCtD
Duloxetine—Anorexia—Memantine—Alzheimer's disease	0.000105	0.000663	CcSEcCtD
Duloxetine—Atomoxetine—CYP2D6—Alzheimer's disease	0.000105	0.0463	CrCbGaD
Duloxetine—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000105	0.000661	CcSEcCtD
Duloxetine—Skin disorder—Rivastigmine—Alzheimer's disease	0.000105	0.000661	CcSEcCtD
Duloxetine—Fatigue—Donepezil—Alzheimer's disease	0.000105	0.000661	CcSEcCtD
Duloxetine—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000105	0.000658	CcSEcCtD
Duloxetine—Pain—Donepezil—Alzheimer's disease	0.000104	0.000655	CcSEcCtD
Duloxetine—Constipation—Donepezil—Alzheimer's disease	0.000104	0.000655	CcSEcCtD
Duloxetine—Dizziness—Galantamine—Alzheimer's disease	0.000104	0.000654	CcSEcCtD
Duloxetine—Anorexia—Rivastigmine—Alzheimer's disease	0.000103	0.000649	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000101	0.000634	CcSEcCtD
Duloxetine—Feeling abnormal—Donepezil—Alzheimer's disease	0.0001	0.000631	CcSEcCtD
Duloxetine—Propranolol—CYP2D6—Alzheimer's disease	0.0001	0.0439	CrCbGaD
Duloxetine—Insomnia—Memantine—Alzheimer's disease	0.0001	0.000629	CcSEcCtD
Duloxetine—Vomiting—Galantamine—Alzheimer's disease	9.99e-05	0.000629	CcSEcCtD
Duloxetine—Gastrointestinal pain—Donepezil—Alzheimer's disease	9.95e-05	0.000627	CcSEcCtD
Duloxetine—Paraesthesia—Memantine—Alzheimer's disease	9.92e-05	0.000625	CcSEcCtD
Duloxetine—Rash—Galantamine—Alzheimer's disease	9.9e-05	0.000623	CcSEcCtD
Duloxetine—Dermatitis—Galantamine—Alzheimer's disease	9.89e-05	0.000623	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	9.85e-05	0.00062	CcSEcCtD
Duloxetine—Headache—Galantamine—Alzheimer's disease	9.84e-05	0.000619	CcSEcCtD
Duloxetine—Somnolence—Memantine—Alzheimer's disease	9.82e-05	0.000618	CcSEcCtD
Duloxetine—Insomnia—Rivastigmine—Alzheimer's disease	9.78e-05	0.000616	CcSEcCtD
Duloxetine—Dyspepsia—Memantine—Alzheimer's disease	9.73e-05	0.000612	CcSEcCtD
Duloxetine—Paraesthesia—Rivastigmine—Alzheimer's disease	9.71e-05	0.000611	CcSEcCtD
Duloxetine—Urticaria—Donepezil—Alzheimer's disease	9.67e-05	0.000609	CcSEcCtD
Duloxetine—Abdominal pain—Donepezil—Alzheimer's disease	9.62e-05	0.000606	CcSEcCtD
Duloxetine—Body temperature increased—Donepezil—Alzheimer's disease	9.62e-05	0.000606	CcSEcCtD
Duloxetine—Somnolence—Rivastigmine—Alzheimer's disease	9.61e-05	0.000605	CcSEcCtD
Duloxetine—Decreased appetite—Memantine—Alzheimer's disease	9.61e-05	0.000605	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Memantine—Alzheimer's disease	9.54e-05	0.000601	CcSEcCtD
Duloxetine—Fatigue—Memantine—Alzheimer's disease	9.53e-05	0.0006	CcSEcCtD
Duloxetine—Dyspepsia—Rivastigmine—Alzheimer's disease	9.52e-05	0.000599	CcSEcCtD
Duloxetine—Constipation—Memantine—Alzheimer's disease	9.45e-05	0.000595	CcSEcCtD
Duloxetine—Pain—Memantine—Alzheimer's disease	9.45e-05	0.000595	CcSEcCtD
Duloxetine—Decreased appetite—Rivastigmine—Alzheimer's disease	9.4e-05	0.000592	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	9.33e-05	0.000588	CcSEcCtD
Duloxetine—Nausea—Galantamine—Alzheimer's disease	9.33e-05	0.000587	CcSEcCtD
Duloxetine—Fatigue—Rivastigmine—Alzheimer's disease	9.32e-05	0.000587	CcSEcCtD
Duloxetine—Pain—Rivastigmine—Alzheimer's disease	9.24e-05	0.000582	CcSEcCtD
Duloxetine—Constipation—Rivastigmine—Alzheimer's disease	9.24e-05	0.000582	CcSEcCtD
Duloxetine—Feeling abnormal—Memantine—Alzheimer's disease	9.11e-05	0.000573	CcSEcCtD
Duloxetine—Gastrointestinal pain—Memantine—Alzheimer's disease	9.04e-05	0.000569	CcSEcCtD
Duloxetine—Hypersensitivity—Donepezil—Alzheimer's disease	8.97e-05	0.000564	CcSEcCtD
Duloxetine—Feeling abnormal—Rivastigmine—Alzheimer's disease	8.91e-05	0.000561	CcSEcCtD
Duloxetine—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	8.84e-05	0.000557	CcSEcCtD
Duloxetine—Urticaria—Memantine—Alzheimer's disease	8.78e-05	0.000553	CcSEcCtD
Duloxetine—Abdominal pain—Memantine—Alzheimer's disease	8.74e-05	0.00055	CcSEcCtD
Duloxetine—Body temperature increased—Memantine—Alzheimer's disease	8.74e-05	0.00055	CcSEcCtD
Duloxetine—Asthenia—Donepezil—Alzheimer's disease	8.73e-05	0.00055	CcSEcCtD
Duloxetine—Pruritus—Donepezil—Alzheimer's disease	8.61e-05	0.000542	CcSEcCtD
Duloxetine—Urticaria—Rivastigmine—Alzheimer's disease	8.59e-05	0.000541	CcSEcCtD
Duloxetine—Abdominal pain—Rivastigmine—Alzheimer's disease	8.55e-05	0.000538	CcSEcCtD
Duloxetine—Body temperature increased—Rivastigmine—Alzheimer's disease	8.55e-05	0.000538	CcSEcCtD
Duloxetine—Diarrhoea—Donepezil—Alzheimer's disease	8.33e-05	0.000524	CcSEcCtD
Duloxetine—Hypersensitivity—Memantine—Alzheimer's disease	8.14e-05	0.000513	CcSEcCtD
Duloxetine—Dizziness—Donepezil—Alzheimer's disease	8.05e-05	0.000507	CcSEcCtD
Duloxetine—Hypersensitivity—Rivastigmine—Alzheimer's disease	7.96e-05	0.000501	CcSEcCtD
Duloxetine—Asthenia—Memantine—Alzheimer's disease	7.93e-05	0.000499	CcSEcCtD
Duloxetine—Pruritus—Memantine—Alzheimer's disease	7.82e-05	0.000492	CcSEcCtD
Duloxetine—Asthenia—Rivastigmine—Alzheimer's disease	7.76e-05	0.000488	CcSEcCtD
Duloxetine—Vomiting—Donepezil—Alzheimer's disease	7.74e-05	0.000487	CcSEcCtD
Duloxetine—Rash—Donepezil—Alzheimer's disease	7.67e-05	0.000483	CcSEcCtD
Duloxetine—Dermatitis—Donepezil—Alzheimer's disease	7.67e-05	0.000483	CcSEcCtD
Duloxetine—Pruritus—Rivastigmine—Alzheimer's disease	7.65e-05	0.000481	CcSEcCtD
Duloxetine—Headache—Donepezil—Alzheimer's disease	7.62e-05	0.00048	CcSEcCtD
Duloxetine—Diarrhoea—Memantine—Alzheimer's disease	7.56e-05	0.000476	CcSEcCtD
Duloxetine—Diarrhoea—Rivastigmine—Alzheimer's disease	7.4e-05	0.000466	CcSEcCtD
Duloxetine—Dizziness—Memantine—Alzheimer's disease	7.31e-05	0.00046	CcSEcCtD
Duloxetine—Nausea—Donepezil—Alzheimer's disease	7.23e-05	0.000455	CcSEcCtD
Duloxetine—Dizziness—Rivastigmine—Alzheimer's disease	7.15e-05	0.00045	CcSEcCtD
Duloxetine—Vomiting—Memantine—Alzheimer's disease	7.03e-05	0.000442	CcSEcCtD
Duloxetine—Rash—Memantine—Alzheimer's disease	6.97e-05	0.000439	CcSEcCtD
Duloxetine—Dermatitis—Memantine—Alzheimer's disease	6.96e-05	0.000438	CcSEcCtD
Duloxetine—Headache—Memantine—Alzheimer's disease	6.92e-05	0.000436	CcSEcCtD
Duloxetine—Vomiting—Rivastigmine—Alzheimer's disease	6.87e-05	0.000433	CcSEcCtD
Duloxetine—Rash—Rivastigmine—Alzheimer's disease	6.82e-05	0.000429	CcSEcCtD
Duloxetine—Dermatitis—Rivastigmine—Alzheimer's disease	6.81e-05	0.000429	CcSEcCtD
Duloxetine—Headache—Rivastigmine—Alzheimer's disease	6.77e-05	0.000426	CcSEcCtD
Duloxetine—Nausea—Memantine—Alzheimer's disease	6.56e-05	0.000413	CcSEcCtD
Duloxetine—Nausea—Rivastigmine—Alzheimer's disease	6.42e-05	0.000404	CcSEcCtD
Duloxetine—CYP2D6—Metabolism—CYP46A1—Alzheimer's disease	1.23e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NPS—Alzheimer's disease	1.23e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PPP3CA—Alzheimer's disease	1.22e-05	0.000245	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL2—Alzheimer's disease	1.22e-05	0.000244	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—F2—Alzheimer's disease	1.21e-05	0.000242	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTK2B—Alzheimer's disease	1.21e-05	0.000242	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AKT1—Alzheimer's disease	1.2e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSENEN—Alzheimer's disease	1.2e-05	0.00024	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ND1—Alzheimer's disease	1.19e-05	0.000239	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ATP5A1—Alzheimer's disease	1.19e-05	0.000238	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CASP3—Alzheimer's disease	1.19e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APH1A—Alzheimer's disease	1.18e-05	0.000236	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—Alzheimer's disease	1.18e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SST—Alzheimer's disease	1.17e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GAB2—Alzheimer's disease	1.17e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK2—Alzheimer's disease	1.17e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CALM1—Alzheimer's disease	1.17e-05	0.000234	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PLCB1—Alzheimer's disease	1.17e-05	0.000234	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GSK3A—Alzheimer's disease	1.16e-05	0.000233	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCSTN—Alzheimer's disease	1.15e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APP—Alzheimer's disease	1.14e-05	0.000229	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLD3—Alzheimer's disease	1.13e-05	0.000227	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—Alzheimer's disease	1.13e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LRP1—Alzheimer's disease	1.12e-05	0.000225	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—INPP5D—Alzheimer's disease	1.12e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—A2M—Alzheimer's disease	1.11e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Alzheimer's disease	1.11e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—F2—Alzheimer's disease	1.1e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PRKCG—Alzheimer's disease	1.1e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GAL—Alzheimer's disease	1.09e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GFAP—Alzheimer's disease	1.09e-05	0.000219	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK8—Alzheimer's disease	1.09e-05	0.000218	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—Alzheimer's disease	1.09e-05	0.000218	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSD17B10—Alzheimer's disease	1.09e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PLCB1—Alzheimer's disease	1.08e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSEN2—Alzheimer's disease	1.08e-05	0.000216	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—Alzheimer's disease	1.06e-05	0.000212	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP46A1—Alzheimer's disease	1.04e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR5—Alzheimer's disease	1.04e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—Alzheimer's disease	1.02e-05	0.000203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ND1—Alzheimer's disease	1.01e-05	0.000202	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGFR—Alzheimer's disease	1.01e-05	0.000202	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—Alzheimer's disease	1.01e-05	0.000202	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CREB1—Alzheimer's disease	1e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PRKCG—Alzheimer's disease	9.95e-06	0.000199	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NPY—Alzheimer's disease	9.9e-06	0.000198	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—Alzheimer's disease	9.86e-06	0.000198	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IAPP—Alzheimer's disease	9.84e-06	0.000197	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADAM10—Alzheimer's disease	9.83e-06	0.000197	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL2—Alzheimer's disease	9.79e-06	0.000196	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—A2M—Alzheimer's disease	9.65e-06	0.000193	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Alzheimer's disease	9.61e-06	0.000192	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CRH—Alzheimer's disease	9.56e-06	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PRKCG—Alzheimer's disease	9.51e-06	0.000191	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR5—Alzheimer's disease	9.43e-06	0.000189	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSEN2—Alzheimer's disease	9.35e-06	0.000187	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—S100B—Alzheimer's disease	9.3e-06	0.000186	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—Alzheimer's disease	9.24e-06	0.000185	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—Alzheimer's disease	9.22e-06	0.000185	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NPS—Alzheimer's disease	9.06e-06	0.000181	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—Alzheimer's disease	9.02e-06	0.000181	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR5—Alzheimer's disease	9.01e-06	0.000181	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PPP3CA—Alzheimer's disease	9.01e-06	0.000181	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—F2—Alzheimer's disease	8.91e-06	0.000178	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTK2B—Alzheimer's disease	8.88e-06	0.000178	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF2—Alzheimer's disease	8.85e-06	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GAB2—Alzheimer's disease	8.64e-06	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SST—Alzheimer's disease	8.64e-06	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK2—Alzheimer's disease	8.64e-06	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKCG—Alzheimer's disease	8.64e-06	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CALM1—Alzheimer's disease	8.61e-06	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NPY—Alzheimer's disease	8.6e-06	0.000172	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GSK3A—Alzheimer's disease	8.57e-06	0.000172	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1R—Alzheimer's disease	8.56e-06	0.000171	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IAPP—Alzheimer's disease	8.55e-06	0.000171	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APP—Alzheimer's disease	8.42e-06	0.000169	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CRH—Alzheimer's disease	8.3e-06	0.000166	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LPL—Alzheimer's disease	8.21e-06	0.000164	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR5—Alzheimer's disease	8.19e-06	0.000164	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MEF2C—Alzheimer's disease	8.13e-06	0.000163	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—F2—Alzheimer's disease	8.09e-06	0.000162	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKCG—Alzheimer's disease	7.98e-06	0.00016	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLCB1—Alzheimer's disease	7.95e-06	0.000159	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NPS—Alzheimer's disease	7.87e-06	0.000158	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PPP3CA—Alzheimer's disease	7.83e-06	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—Alzheimer's disease	7.77e-06	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGF—Alzheimer's disease	7.77e-06	0.000156	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—F2—Alzheimer's disease	7.73e-06	0.000155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTK2B—Alzheimer's disease	7.71e-06	0.000155	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CHAT—Alzheimer's disease	7.68e-06	0.000154	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPI1—Alzheimer's disease	7.68e-06	0.000154	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—Alzheimer's disease	7.61e-06	0.000152	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR5—Alzheimer's disease	7.56e-06	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GAB2—Alzheimer's disease	7.5e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SST—Alzheimer's disease	7.5e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK2—Alzheimer's disease	7.5e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CALM1—Alzheimer's disease	7.47e-06	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GSK3A—Alzheimer's disease	7.44e-06	0.000149	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGFR—Alzheimer's disease	7.41e-06	0.000149	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—Alzheimer's disease	7.4e-06	0.000148	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CREB1—Alzheimer's disease	7.37e-06	0.000148	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MAOB—Alzheimer's disease	7.36e-06	0.000147	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APP—Alzheimer's disease	7.31e-06	0.000146	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADAM10—Alzheimer's disease	7.24e-06	0.000145	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL2—Alzheimer's disease	7.21e-06	0.000144	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GAPDH—Alzheimer's disease	7.08e-06	0.000142	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	7.08e-06	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—F2—Alzheimer's disease	7.02e-06	0.000141	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—Alzheimer's disease	6.96e-06	0.000139	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CALM1—Alzheimer's disease	6.9e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLCB1—Alzheimer's disease	6.9e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—Alzheimer's disease	6.88e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—Alzheimer's disease	6.88e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—S100B—Alzheimer's disease	6.85e-06	0.000137	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—A2M—Alzheimer's disease	6.84e-06	0.000137	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CAV1—Alzheimer's disease	6.82e-06	0.000137	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ESR1—Alzheimer's disease	6.57e-06	0.000132	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—Alzheimer's disease	6.52e-06	0.000131	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPI1—Alzheimer's disease	6.5e-06	0.00013	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CHAT—Alzheimer's disease	6.5e-06	0.00013	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—F2—Alzheimer's disease	6.49e-06	0.00013	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGFR—Alzheimer's disease	6.44e-06	0.000129	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—Alzheimer's disease	6.42e-06	0.000129	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CREB1—Alzheimer's disease	6.4e-06	0.000128	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH1—Alzheimer's disease	6.35e-06	0.000127	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1R—Alzheimer's disease	6.3e-06	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADAM10—Alzheimer's disease	6.29e-06	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—Alzheimer's disease	6.26e-06	0.000125	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MAOB—Alzheimer's disease	6.23e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—Alzheimer's disease	6.04e-06	0.000121	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GAPDH—Alzheimer's disease	6e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MEF2C—Alzheimer's disease	5.99e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GSK3B—Alzheimer's disease	5.96e-06	0.000119	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ACHE—Alzheimer's disease	5.95e-06	0.000119	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S100B—Alzheimer's disease	5.95e-06	0.000119	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	5.93e-06	0.000119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREB1—Alzheimer's disease	5.91e-06	0.000118	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	5.88e-06	0.000118	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	5.88e-06	0.000118	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—Alzheimer's disease	5.88e-06	0.000118	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCG—Alzheimer's disease	5.88e-06	0.000118	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—A2M—Alzheimer's disease	5.8e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—Alzheimer's disease	5.78e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGF—Alzheimer's disease	5.72e-06	0.000115	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—Alzheimer's disease	5.68e-06	0.000114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—Alzheimer's disease	5.66e-06	0.000113	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO1—Alzheimer's disease	5.58e-06	0.000112	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	5.58e-06	0.000112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—Alzheimer's disease	5.57e-06	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1R—Alzheimer's disease	5.47e-06	0.00011	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—Alzheimer's disease	5.45e-06	0.000109	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—Alzheimer's disease	5.25e-06	0.000105	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MEF2C—Alzheimer's disease	5.2e-06	0.000104	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—Alzheimer's disease	5.18e-06	0.000104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	5.17e-06	0.000104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—Alzheimer's disease	5.15e-06	0.000103	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCG—Alzheimer's disease	5.1e-06	0.000102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CALM1—Alzheimer's disease	5.08e-06	0.000102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—Alzheimer's disease	5.07e-06	0.000101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—Alzheimer's disease	5.07e-06	0.000101	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ACHE—Alzheimer's disease	5.04e-06	0.000101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—Alzheimer's disease	5.02e-06	0.000101	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INPP5D—Alzheimer's disease	4.98e-06	9.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGF—Alzheimer's disease	4.97e-06	9.96e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	4.89e-06	9.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—Alzheimer's disease	4.84e-06	9.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—Alzheimer's disease	4.84e-06	9.69e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—Alzheimer's disease	4.78e-06	9.57e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	4.74e-06	9.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO1—Alzheimer's disease	4.72e-06	9.46e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	4.72e-06	9.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—Alzheimer's disease	4.68e-06	9.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	4.63e-06	9.28e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—Alzheimer's disease	4.42e-06	8.85e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALM1—Alzheimer's disease	4.41e-06	8.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—Alzheimer's disease	4.4e-06	8.81e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—Alzheimer's disease	4.4e-06	8.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—Alzheimer's disease	4.39e-06	8.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GSK3B—Alzheimer's disease	4.39e-06	8.79e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—Alzheimer's disease	4.38e-06	8.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—Alzheimer's disease	4.36e-06	8.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREB1—Alzheimer's disease	4.35e-06	8.72e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—Alzheimer's disease	4.35e-06	8.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—Alzheimer's disease	4.33e-06	8.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—Alzheimer's disease	4.26e-06	8.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—Alzheimer's disease	4.2e-06	8.41e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—Alzheimer's disease	4.19e-06	8.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—Alzheimer's disease	4.15e-06	8.31e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	4.14e-06	8.3e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	4.09e-06	8.19e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	4.07e-06	8.15e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.07e-06	8.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—Alzheimer's disease	4.06e-06	8.13e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—Alzheimer's disease	4.02e-06	8.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	4.02e-06	8.05e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—Alzheimer's disease	4.01e-06	8.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GSK3B—Alzheimer's disease	3.81e-06	7.63e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—Alzheimer's disease	3.8e-06	7.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREB1—Alzheimer's disease	3.78e-06	7.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—Alzheimer's disease	3.76e-06	7.53e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—Alzheimer's disease	3.72e-06	7.45e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—Alzheimer's disease	3.71e-06	7.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—Alzheimer's disease	3.7e-06	7.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—Alzheimer's disease	3.64e-06	7.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	3.46e-06	6.94e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	3.45e-06	6.9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—Alzheimer's disease	3.41e-06	6.83e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	3.35e-06	6.71e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—Alzheimer's disease	3.3e-06	6.6e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—Alzheimer's disease	3.25e-06	6.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—Alzheimer's disease	3.22e-06	6.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—Alzheimer's disease	3.2e-06	6.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—Alzheimer's disease	3.15e-06	6.31e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CALM1—Alzheimer's disease	3.13e-06	6.27e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—Alzheimer's disease	3.12e-06	6.25e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—Alzheimer's disease	3.09e-06	6.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—Alzheimer's disease	2.96e-06	5.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—Alzheimer's disease	2.95e-06	5.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	2.84e-06	5.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.82e-06	5.66e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—Alzheimer's disease	2.81e-06	5.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—Alzheimer's disease	2.8e-06	5.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—Alzheimer's disease	2.78e-06	5.57e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—Alzheimer's disease	2.73e-06	5.48e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—Alzheimer's disease	2.72e-06	5.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—Alzheimer's disease	2.66e-06	5.34e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CALM1—Alzheimer's disease	2.65e-06	5.31e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—Alzheimer's disease	2.64e-06	5.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—Alzheimer's disease	2.62e-06	5.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—Alzheimer's disease	2.57e-06	5.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—Alzheimer's disease	2.57e-06	5.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—Alzheimer's disease	2.56e-06	5.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—Alzheimer's disease	2.51e-06	5.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—Alzheimer's disease	2.37e-06	4.76e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—Alzheimer's disease	2.37e-06	4.75e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—Alzheimer's disease	2.34e-06	4.68e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—Alzheimer's disease	2.3e-06	4.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—Alzheimer's disease	2.26e-06	4.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—Alzheimer's disease	2.18e-06	4.37e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	2.14e-06	4.28e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—Alzheimer's disease	2.07e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—Alzheimer's disease	1.98e-06	3.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—Alzheimer's disease	1.89e-06	3.79e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	1.81e-06	3.63e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—Alzheimer's disease	1.79e-06	3.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—Alzheimer's disease	1.74e-06	3.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—Alzheimer's disease	1.64e-06	3.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—Alzheimer's disease	1.52e-06	3.03e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—Alzheimer's disease	1.07e-06	2.15e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—Alzheimer's disease	9.1e-07	1.82e-05	CbGpPWpGaD
